
(插ttps://www.coronavirus.gov) (插ttps://www.nih.gov/coronavirus)



## Atlanta Site Added to NIH Clinical Trial of a Vaccine for COVID-19

March 27, 2020

Adults who are interested in joining this study should contact <u>vaccine@emory.edu (mailto:vaccine@emory.edu)</u> (for the Hope Clinic in Decatur) or <u>ecc.vaccine@emory.edu (mailto:ecc.vaccine@emory.edu)</u> (for the Emory campus in Atlanta). People who live outside of this region will not be eligible to participate in this trial.

Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.

Credit: NIAID

Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in a Phase 1 clinical trial of an investigational vaccine designed to prevent coronavirus disease 2019 (COVID-19). The trial, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, began last week at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. KPWHRI and Emory are part of NIAID's Infectious Diseases Clinical Research Consortium (https://www.nih.gov/news-events/news-releases/infectious-diseases-clinical-research-consortium-awards-announced)

The trial aims to enroll a total of 45 participants across the two sites. NIAID scientists and clinicians have been closely monitoring the outbreak of COVID-19 in Washington and throughout the United States. They decided to expand the trial to another geographic area to ensure efficient enrollment.

Evan Anderson, M.D., associate professor of pediatrics and medicine, and Nadine Rouphael, M.D., associate professor of medicine, will lead the study at Emory. Participants will receive two shots of the experimental vaccine approximately one month apart and will be followed for approximately one year. The vaccine, called mRNA-1273, was developed by scientists at

NIAID's Vaccine Research Center and the biotechnology company Moderna, Inc. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.

For more details on the trial, please see <a href="NIAID's March 16 press release">NIAID's March 16 press release</a> (/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins) and visit ClinicalTrials.gov and search identifier <a href="NCT04283461">NCT04283461</a> Adults in the Atlanta area who are interested in joining this study should contact <a href="vaccine@emory.edu">vaccine@emory.edu</a> (for the Hope Clinic in Decatur) or <a href="mailto:ecc.vaccine@emory.edu">ecc.vaccine@emory.edu</a> (for the Emory campus in Atlanta).

## Contact

## **Submit a Media Request**

Contact the NIAID News & Science Writing Branch.
301-402-1663
niaidnews@niaid.nih.gov (mailto:niaidnews@niaid.nih.gov)
All Media Contacts (/news-events/media-contacts)

## Related Content

BEI Resources Repository (/research/bei-resources-repository)

Preclinical Models of Infectious Disease (/research/pre-clinical-models-infectious-disease)

Biocontainment Laboratory: Tulane University (/research/tulane-university-regional-biocontainment-lab)

Biocontainment Laboratory: Rutgers University (/research/rutgers-regional-biocontainment-lab)

Genomic Centers for Infectious Diseases (GCID) Resources (/research/gcid-resources)

Content last reviewed on March 27, 2020